On the occasion of the 2nd International Congress on Prediabetes and the Metabolic Syndrome held in Barcelona, Spain, April 25-28, 2007, the initiation of the Acarbose Cardiovascular Evaluation (ACE) was announced.
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved an update to the ORENCIA? (abatacept) product labeling regarding the progression of structural joint damage — an important measure in the treatment of rheumatoid arthritis (RA).
Abbott announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA? (adalimumab) for the treatment of severe Crohn’s disease.
Researchers at Johns Hopkins have discovered to their surprise that a drug commonly used to treat toenail fungus can also block angiogenesis, the growth of new blood vessels commonly seen in cancers.
The herbal medicine Dan Shen, a standard treatment for ischemic stroke in China, lacks strong scientific evidence to support such use, according a new review of studies.
Taking low dose aspirin does not protect older women against cognitive decline, finds a large study published online in the BMJ today.
Today’s news that the Food and Drug Administration (FDA) is examining whether the maker of Zyprexa failed to submit clinical trial data about the harmful side effects of the antipsychotic drug underscores the urgent need for Congress to pass drug-safety legislation.
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today statistically significant results with BEMA Fentanyl in cancer patients with breakthrough pain in its pivotal Phase III efficacy clinical trial for the product.
The U.S. Food and Drug Administration (FDA) has caused an unnecessary scare about some pain relievers by adding a warning to drugs that are safe, says Curt Furberg, M.D., Ph.D., from Wake Forest University School of Medicine.
The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.